KOSDAQBiotech & Pharma196300

HLB Pep

₩3,060▲ 0.33%2026-11-18 close
Market Cap
₩29.1B
Turnover
₩10,657,030
Volume
3.5K
Shares out.
9.5M
PER
—
PBR
1.3×
EPS
-₩120
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

First overseas approval; turning the loss structure is the test

HLB Pep secured its first overseas approval for a finished drug built on its own peptide API, but with 2025 revenue of KRW 4.96 billion and an operating loss of KRW 7.32 billion, turning the earnings structure remains the main task.

  1. 1

    The Mexican marketing approval announced on November 10, 2026 is the first overseas approval of a finished drug using HLB Pep's API. Because Mexico recognized Korea's MFDS as a reference regulator, the API was also accepted without a separate on-site inspection.

  2. 2

    On a DART-disclosed basis, 2025 revenue was KRW 4.96 billion, down 20.3% year on year, and the operating loss widened to KRW 7.32 billion. The company has posted losses for four consecutive years from 2022 through 2025.

  3. 3

    Revenue in Q3 2026 was KRW 1.3 billion, and the operating loss has narrowed for three straight quarters since Q1 2026 to KRW 1.06 billion. However, the company has recorded an operating loss in each of the five quarters from Q3 2025 through Q3 2026.

  4. 4

    Total liabilities at the end of 2025 were KRW 28.1 billion, above total equity of KRW 25.7 billion, and operating cash flow in 2025 was -KRW 5.57 billion, a larger outflow than the prior year.

  5. 5

    New businesses including an obesity candidate, a radiopharmaceutical cancer drug and a curcumin cosmetic are at preclinical or early commercial stages, so the timing of any earnings contribution is not yet clear.

02

Business structure

HLB Pep, formerly Anien, was founded in 2000 as a peptide biomaterials company and listed on KOSDAQ in 2016. The company manufactures and sells medical and research peptide materials and operates GMP plants in Jangseong and Osong.

Its core products are peptide APIs, including leuprorelin used for precocious puberty and prostate cancer, ganirelix for infertility, vasopressin and desmopressin. After the HLB Group acquisition in March 2025, the company expanded its large-scale peptide synthesis and high-grade purification equipment.

Customers were mainly Korean pharmaceutical companies, but in January 2026 HLB Pep signed a clinical API manufacturing contract with a neurology-focused developer for an ALS treatment worth KRW 765 million. Its beauty unit has launched a curcumin peptide cosmetic and is building a dermatology brand called LABSENN.

In drug development, the obesity candidate AGM-217 is a GLP-1 and glucagon dual agonist, and the company is developing a radiopharmaceutical cancer therapy based on the AGM-330 peptide with a partner.

According to the company, competitiveness depends on purity and the range of peptides it can handle, and its CEO cited Samsung Biologics as the global benchmark.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.2B-₩1.4B−119.3%
2025Q4₩1.5B-₩3.2B−215.9%
2026Q1₩1.6B-₩1.8B−111.5%
2026Q2₩1.3B-₩1.4B−109.8%
2026Q3₩1.3B-₩1.1B−81.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩8.7B-₩4.3B-₩6.2B−49.9%−46.3%93.2%
2023₩5.6B-₩6.7B-₩9.1B−119.7%−86.3%99.6%
2024₩6.2B-₩5.4B-₩6.8B−87.3%−126.2%207.0%
2025₩5B-₩7.3B-₩600M−147.5%−2.5%109.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a DART-disclosed basis, revenue fell from KRW 8.66 billion in 2022 to KRW 5.61 billion in 2023, a 35.2% decline, rebounded to KRW 6.23 billion in 2024, up 11.0%, and then dropped to KRW 4.96 billion in 2025, down 20.3%. 2022 was the largest year in the period and 2025 the smallest.

Operating losses were KRW 4.32 billion in 2022, KRW 6.72 billion in 2023, KRW 5.44 billion in 2024 and KRW 7.32 billion in 2025, a run of four consecutive loss-making years from 2022 through 2025.

In 2025 revenue fell while the operating loss widened, pushing the operating margin to -147.5%, compared with -87.3% in 2024.

According to a December 2025 press report based on electronic disclosures, cost of sales in the first nine months of 2025 was KRW 4.5 billion, above revenue of KRW 3.5 billion, producing a gross loss of KRW 1 billion.

Net loss attributable to controlling shareholders peaked at KRW 9.08 billion in 2023, then narrowed to KRW 6.79 billion in 2024 and KRW 642 million in 2025.

The narrower controlling-shareholder loss in 2025, despite a wider operating loss, appears to reflect non-operating items, and the composition should be checked in the annual report notes. Net loss including non-controlling interests was also KRW 642 million in 2025.

By quarter, revenue was KRW 1.17 billion in Q3 2025, KRW 1.47 billion in Q4 2025, KRW 1.64 billion in Q1 2026, KRW 1.26 billion in Q2 2026 and KRW 1.3 billion in Q3 2026.

The operating loss peaked at KRW 3.17 billion in Q4 2025 and then narrowed to KRW 1.83 billion, KRW 1.38 billion and KRW 1.06 billion over the next three quarters.

In Q4 2025 the controlling-shareholder result turned to a profit of KRW 2.6 billion despite the operating loss, and in Q1 2026 it swung back to a loss of KRW 3 billion. The combined controlling-shareholder net loss for the last four quarters is KRW 1.46 billion.

05

Industry analysis

Peptide APIs and CDMO services operate within a model in which large pharmaceutical companies outsource production. The CEO pointed to the growth of the peptide market and the company's own manufacturing capacity as reasons for investing.

Among Korean biologics CDMO players, Samsung Biologics is often cited as the benchmark for scale and globalization, and the new CEO reported in the press said HLB Pep remains confined to the domestic market and that going global, as Samsung Biologics has, is the most important goal.

According to the company, the competitiveness of peptide CDMO depends on how many peptide materials it can cover and on high purity.

On regulation, after Mexico recognized Korea's MFDS as a reference regulator, HLB Pep's API with a Korean GMP compliance determination and a Drug Master File was accepted without a separate on-site inspection.

In the United States, FDA DMF registration serves as the gateway for API supply, and the company is advancing this process step by step for leuprorelin and other APIs. For overseas sales, the company said it has formed a partnership with InterChem in the United States to build a structure for winning customer orders.

Within the industry, lower utilization and a larger share of outsourcing costs have been cited as factors that weighed on profitability in 2025. Market commentary also suggests that the ability to improve cost ratios and product mix matters more than peptide demand itself.

06

Outlook

In January 2026 the company said its CDMO orders were rising and its automation buildout was on track, and it called 2026 the year to raise shareholder value.

Following the Mexican approval in November 2026, the company plans to expand overseas registrations for its peptide APIs, including leuprorelin, desmopressin, ganirelix and vasopressin. The FDA DMF registration process is also advancing step by step.

In July 2026, news reports covered the FDA registration of the vasopressin API. On overseas customers, a custom anticancer peptide CDMO contract with a Japanese cell therapy company was reported in March 2026, and in May 2026 the company announced an expanded CDMO partnership with Japan's Peptigross.

The ALS-related contract with a neurology developer is a clinical API manufacturing job aimed at a standard consistent with FDA Phase 1 requirements, and its execution will indicate the scale of clinical API demand.

In drug development, the GLP-1 and glucagon dual agonist AGM-217 is undergoing non-clinical toxicity testing in Japan, and the company has outlined microneedle patch and long-acting formulation plans. The radiopharmaceutical cancer candidate AGM-330 is being developed under a joint development agreement with Raymed.

In beauty, the curcumin peptide cosmetic has launched, and the company aims to grow the LABSENN dermatology brand into a cash generator. Because operating losses continued through the first three quarters of 2026, the timing of these businesses' contribution to earnings should be checked in disclosures.

07

Valuation

PER
—
PBR
1.3×
ROE
-6.3%
EPS
-₩120
BPS
₩2,714
Dividend per share
₩0

HLB Pep's price-to-book ratio sits at a level above its book net asset value. Total equity at the end of 2025 was KRW 25.7 billion, all of it attributable to controlling shareholders, so how much the market is paying above net assets is the starting point of any valuation discussion.

PER cannot be calculated because the last four quarters show a net loss. On an annual basis, the controlling-shareholder net loss narrowed from KRW 9.08 billion in 2023 to KRW 642 million in 2025, but the operating loss did not narrow over the same period. The company pays no dividend.

The debt-to-equity ratio fell from 207.0% in 2024 to 109.1% in 2025, yet total liabilities of KRW 28.1 billion still exceed total equity of KRW 25.7 billion. How the valuation reads depends on whether the operating loss actually shrinks and whether overseas API supply shows up as revenue.

In a history of losses, the direction of earnings recovery is the key reference point for any multiple comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

First overseas approval secured

In November 2026 Mexico's regulator approved a Korean finished drug that uses HLB Pep's leuprorelin API. It is the first time a finished drug using the company's API has received overseas approval. Mexico's recognition of MFDS opened a streamlined review route. The company plans to use this approval as a base to expand overseas API supply.

New contract and FDA registration steps

In January 2026 the company disclosed a clinical API manufacturing contract for an ALS treatment with a neurology developer, worth KRW 765 million. Major APIs including leuprorelin, ganirelix and vasopressin are advancing through FDA review in sequence. Whether contract execution and registrations turn into actual revenue is the point to verify.

Obesity and radiopharmaceutical pipeline

The obesity candidate AGM-217 is a dual agonist targeting the GLP-1 and glucagon receptors and is in non-clinical toxicity testing in Japan. The radiopharmaceutical candidate AGM-330 is being developed under a joint development agreement with Raymed. The beauty unit has launched its curcumin peptide product. Whether these drugs enter clinical stages will be a key milestone for the pipeline.

09

Bear factors

Revenue decline and continued losses

Revenue in 2025 was KRW 4.96 billion, down 20.3% year on year, and the operating loss widened to KRW 7.32 billion. Q2 2026 revenue fell 23.4% from the prior quarter. Press reports said cost of sales exceeded revenue in the first nine months of 2025, producing a gross loss.

Debt burden and cash outflow

Total liabilities at the end of 2025 were KRW 28.1 billion, above total equity of KRW 25.7 billion. The debt-to-equity ratio fell from 207.0% in 2024 to 109.1% in 2025 but remains above 100%. Operating cash flow was -KRW 5.57 billion in 2025, a bigger outflow than the -KRW 2.1 billion in 2024. If cash continues to leave the business without earnings recovery, the need for additional funding rises.

Incomplete quarterly improvement

The Q3 2026 operating loss narrowed to KRW 1.06 billion, but revenue of KRW 1.3 billion rose only 11.0% year on year. Among the last five quarters, only Q4 2025 showed a profit at the controlling-shareholder level.

That profit appeared alongside an operating loss of KRW 3.17 billion, so it is hard to read as an operating improvement. Whether the earnings recovery comes from the core business needs to be checked.

10

Risk factors

Financial and liquidity

At the end of 2025, total liabilities of KRW 28.1 billion exceeded total equity of KRW 25.7 billion, and operating cash flow was -KRW 5.57 billion. The operating loss was largest in Q4 2025 at KRW 3.17 billion, and operating losses have continued for five straight quarters through Q3 2026. If additional funding becomes necessary, dilution or higher debt could affect the shareholder structure.

Business concentration and cost structure

Revenue depends mainly on peptide APIs and research services, and the decline in medical peptide materials is cited as a reason for the 2025 deterioration. Causes of cost of sales exceeding revenue are cited as a mix of lower utilization, higher outsourcing and a growing share of low-margin research services. Market observers have warned that if cost ratios do not improve, higher sales could increase losses.

Governance and management structure

The largest shareholder and related parties reported holdings of 40.99% as of April 15, 2026, and related-party convertible bond holdings rose after a conversion price adjustment. Press reports covered a new CEO appointment, but a company announcement in the same period was issued under the name of the existing CEO. The formal start date and management direction still need to be confirmed.

11

What to watch next

  1. By late November 2026

    Whether the new CEO formally takes office and the direction of management. The key question is whether comments on globalization and organizational change lead to concrete execution plans.

  2. After December 2026 (timing undisclosed)

    Whether overseas API supply contracts are disclosed after the Mexican approval. Any such disclosures would show the scale and timing of overseas revenue contribution.

  3. Around late March 2027 (annual report filing deadline)

    Annual revenue, operating loss and operating cash flow in the 2026 annual report. The key check is whether the narrowing operating loss seen in the first three quarters of 2026 holds on a full-year basis.

  4. Timing undisclosed (rolling)

    Results of FDA DMF registrations for leuprorelin and vasopressin, and the non-clinical results for AGM-217. U.S. registrations bear on expanding U.S. API supply, and the non-clinical data indicate whether the pipeline can move to the next stage.

12

Overall view

HLB Pep is a biomaterials company centered on peptide APIs and CDMO services. On a DART-disclosed basis, 2025 revenue fell to KRW 4.96 billion and the operating loss widened to KRW 7.32 billion, a run of four consecutive loss-making years from 2022 through 2025.

Through 2026, quarterly revenue has stayed in a range of about KRW 1.26 billion to KRW 1.64 billion, and the operating loss narrowed each quarter to KRW 1.06 billion in Q3 2026. Over the same period, the controlling-shareholder net loss narrowed from KRW 3 billion in Q1 to KRW 318 million in Q3.

However, operating losses have continued for five consecutive quarters from Q3 2025 through Q3 2026, so a turn in the earnings structure is not yet evident. On the regulatory side, the November 2026 Mexican approval is the first overseas approval of a finished drug using the company's API.

The obesity candidate, radiopharmaceutical candidate and cosmetic are at preclinical or early commercial stages, so the timing of any earnings contribution is unclear. Liabilities still exceed equity, so cash flow and funding needs also need to be tracked.

The next checkpoints are the operating margin in the 2026 annual report, the size of overseas API supply contracts, and changes in the management structure.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. etoday.co.kr
  2. wowtv.co.kr
  3. bloter.net
  4. m.news.nate.com
  5. m.news.nate.com
  6. thebionews.net
  7. comp.wisereport.co.kr
  8. alphabiz.co.kr
  9. medicopharma.co.kr
  10. wowtv.co.kr
  11. wowtv.co.kr
  12. fnnews.com
  13. m.news.nate.com
  14. fnnews.com
  15. fntimes.com
  16. news.nate.com
  17. cbci.co.kr
  18. medifonews.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis